Literature DB >> 8345832

Hypernatremia in the acutely ill elderly patients: role of impaired arginine-vasopressin secretion.

M Sonnenblick1, N Algur.   

Abstract

Hypernatremia, a common finding among the elderly, is believed to be due to water deficit. In the present study, in 12 consecutive hospitalized elderly patients (mean age 82.2 years) with moderate to severe hypernatremia (mean serum sodium 166.9 mEq/l), inappropriately low plasma levels of vasopressin were found in relation to serum osmolality (mean 1.8 pg/ml and 343 mosmol/l, respectively). All patients but 1 were hospitalized with acute febrile disease and all but 2 had underlying neurological disease. Hypernatremia persisted for at least 3 days despite the patients' rehydration. It seems, therefore, that temporary hypernatremia in elderly patients with acute febrile disease, especially in the presence of underlying neurological disorder, reflects an inadequate vasopressin response to the hyperosmolar state.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8345832

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  3 in total

1.  A cross-sectional study on the prevalence of electrolyte abnormalities in multiple trauma patients in Hamedan, Iran.

Authors:  Bareza Rezaei; Einaz Ramazani; Rahimpour Amiri; Zahra Sanaei
Journal:  Health Sci Rep       Date:  2021-03-10

2.  General characteristics of patients with electrolyte imbalance admitted to emergency department.

Authors:  Arif Kadri Balcı; Ozlem Koksal; Ataman Kose; Erol Armagan; Fatma Ozdemir; Taylan Inal; Nuran Oner
Journal:  World J Emerg Med       Date:  2013

3.  Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America.

Authors:  Kevin P High; Suzanne F Bradley; Stefan Gravenstein; David R Mehr; Vincent J Quagliarello; Chesley Richards; Thomas T Yoshikawa
Journal:  J Am Geriatr Soc       Date:  2009-03       Impact factor: 5.562

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.